Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors. Virol J 2011 Jan 26;8:40
Date
01/29/2011Pubmed ID
21269468Pubmed Central ID
PMC3041771DOI
10.1186/1743-422X-8-40Scopus ID
2-s2.0-79251535312 (requires institutional sign-in at Scopus site) 34 CitationsAbstract
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening of novel anti-CMV compounds.
Author List
He R, Sandford G, Hayward GS, Burns WH, Posner GH, Forman M, Arav-Boger RAuthor
Ravit Boger MD Chief, Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antiviral AgentsCell Line
Cytomegalovirus
Cytomegalovirus Infections
Drug Evaluation, Preclinical
Gene Expression
Humans
Luciferases
Promoter Regions, Genetic
Recombinant Proteins
